
NYSE:MCK
Management team seems to be exceptionally strong. Bought a number of companies over the last couple of years and just completed a big acquisition in Germany which makes them a big, significant, generics distributor in Europe which will be accretive to earnings. Looking out a couple of years, he could see $11-$12 in earnings. Very, very good at execution. Yield of 0.54%.
Likes it a lot, but doesn’t own it because he has a lot of healthcare. Really benefited from a pickup in volumes. Well poised to benefit from the US healthcare act.